期刊文献+

Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development 被引量:3

Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development
下载PDF
导出
摘要 AIM: To investigate risk factors for development of hepatocellular carcinoma(HCC) in patients with hepatitis C virus-related liver cirrhosis(LC-C).METHODS: To evaluate the relationship between clinical factors including virological response and the development of HCC in patients with LC-C treated with interferon(IFN) and ribavirin, we conducted a multicenter, retrospective study in 14 hospitals in Japan. All patients had compensated LC-C with clinical or histological data available. HCC was diagnosed by the presence of typical hypervascular characteristics on computed tomography and/or magnetic resonance imaging.RESULTS: HCC was diagnosis in 50(21.6%) of 231 LC-C patients during a median observation period of 3.8 years after IFN and ribavirin therapy. Patients who developed HCC were older(P = 0.018) and had higher serum levels of pretreatment alpha-fetoprotein(AFP)(P = 0.038). Multivariate analysis revealed the following independent risk factors for HCC development: history of treatment for HCC [P < 0.001, odds ratio(OR) = 15.27, 95%CI: 4.98-59.51], AFP levels of ≥ 10 ng/m L(P = 0.009, OR = 3.89, 95%CI: 1.38-11.94), and des-γ-carboxy prothrombin(DCP) levels of ≥ 40 m AU/mL at 24 wk after the completion of IFN and ribavirin therapy(P < 0.001, OR = 24.43, 95%CI: 4.11-238.67).CONCLUSION: We suggested that the elevation of AFP and DCP levels at 24 wk after the completion of IFN and ribavirin therapy were strongly associated with the incidence of HCC irrespective of virological response among Japanese LC-C patients. AIM: To investigate risk factors for development of hepatocellular carcinoma(HCC) in patients with hepatitis C virus-related liver cirrhosis(LC-C).METHODS: To evaluate the relationship between clinical factors including virological response and the development of HCC in patients with LC-C treated with interferon(IFN) and ribavirin, we conducted a multicenter, retrospective study in 14 hospitals in Japan. All patients had compensated LC-C with clinical or histological data available. HCC was diagnosed by the presence of typical hypervascular characteristics on computed tomography and/or magnetic resonance imaging.RESULTS: HCC was diagnosis in 50(21.6%) of 231 LC-C patients during a median observation period of 3.8 years after IFN and ribavirin therapy. Patients who developed HCC were older(P = 0.018) and had higher serum levels of pretreatment alpha-fetoprotein(AFP)(P = 0.038). Multivariate analysis revealed the following independent risk factors for HCC development: history of treatment for HCC [P < 0.001, odds ratio(OR) = 15.27, 95%CI: 4.98-59.51], AFP levels of ≥ 10 ng/m L(P = 0.009, OR = 3.89, 95%CI: 1.38-11.94), and des-γ-carboxy prothrombin(DCP) levels of ≥ 40 m AU/mL at 24 wk after the completion of IFN and ribavirin therapy(P < 0.001, OR = 24.43, 95%CI: 4.11-238.67).CONCLUSION: We suggested that the elevation of AFP and DCP levels at 24 wk after the completion of IFN and ribavirin therapy were strongly associated with the incidence of HCC irrespective of virological response among Japanese LC-C patients.
出处 《World Journal of Hepatology》 CAS 2015年第27期2757-2764,共8页 世界肝病学杂志(英文版)(电子版)
基金 Supported by A Grant--in--Aid from the Japanese Ministry of Health,Welfare and Labour
关键词 Des-γ-carboxy PROTHROMBIN HEPATOCELLULAR carcinoma Des-γ-carboxy prothrombin Hepatocellular carcinoma
  • 相关文献

参考文献20

  • 1Naoki Yamashita,Aritsune Ohho,Akihiro Yamasaki,Miho Kurokawa,Kazuhiro Kotoh,Eiji Kajiwara.Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes[J]. Journal of Gastroenterology . 2014 (11)
  • 2Eric Lawitz,Fred F Poordad,Phillip S Pang,Robert H Hyland,Xiao Ding,Hongmei Mo,William T Symonds,John G McHutchison,Fernando E Membreno.Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial[J]. The Lancet . 2013
  • 3Yukio Osaki,Yoshihide Ueda,Hiroyuki Marusawa,Jun Nakajima,Toru Kimura,Ryuichi Kita,Hiroki Nishikawa,Sumio Saito,Shinichiro Henmi,Azusa Sakamoto,Yuji Eso,Tsutomu Chiba.Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study[J]. Journal of Gastroenterology . 2012 (4)
  • 4Kazuhiro Kasai,Akira Ushio,Yukiho Kasai,Kei Sawara,Yasuhiro Miyamoto,Kanta Oikawa,Hidekatsu Kuroda,Yasuhiro Takikawa,Kazuyuki Suzuki.Therapeutic efficacy of combination therapy with intra‐arterial 5‐fluorouracil and systemic pegylated interferon α‐2b for advanced hepatocellular carcinoma with portal venous invasion[J]. Cancer . 2011 (13)
  • 5Anna S. Lok,James E. Everhart,Elizabeth C. Wright,Adrian M. Di Bisceglie,Hae–Young Kim,Richard K. Sterling,Gregory T. Everson,Karen L. Lindsay,William M. Lee,Herbert L. Bonkovsky,Jules L. Dienstag,Marc G. Ghany,Chihiro Morishima,Timothy R. Morgan.Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C[J].Gastroenterology.2011(3)
  • 6Ying-Chun Shen,Chiun Hsu,Li-Tzong Chen,Chia-Chi Cheng,Fu-Chang Hu,Ann-Lii Cheng.Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach[J]. Journal of Hepatology . 2010 (6)
  • 7Ana-Carolina Cardoso,Rami Moucari,Claudio Figueiredo-Mendes,Marie-Pierre Ripault,Nathalie Giuily,Corinne Castelnau,Nathalie Boyer,Tarik Asselah,Michelle Martinot-Peignoux,Sarah Maylin,Roberto J. Carvalho-Filho,Dominique Valla,Pierre Bedossa,Patrick Marcellin.Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis[J]. Journal of Hepatology . 2010 (5)
  • 8Y.Miyake,A.Takaki,Y.Iwasaki,K.Yamamoto.Meta‐analysis: interferon‐alpha prevents the recurrence after curative treatment of hepatitis C virus‐related hepatocellular carcinoma[J]. Journal of Viral Hepatitis . 2010 (4)
  • 9Kiminori Uka,Hiroshi Aikata,Shintaro Takaki,Daiki Miki,Tomokazu Kawaoka,Soo Cheol Jeong,Shoichi Takahashi,Naoyuki Toyota,Katsuhide Ito,Kazuaki Chayama.Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma[J]. Journal of Gastroenterology . 2007 (10)
  • 10Tsung‐MingChen,Pi‐TehHuang,Ming‐HungTsai,Lien‐FuLin,Chung‐ChengLiu,Ka‐SicHo,Chuan‐PauSiauw,Po‐LiangChao,Jai‐NienTung.Predictors of alpha‐fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a–ribavirin combination therapy[J]. Journal of Gastroenterology and Hepatology . 2007 (5)

共引文献16

同被引文献19

引证文献3

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部